Cargando…

Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC

INTRODUCTION: Co-occurring mutations in KRAS-mutant NSCLC are associated with discrete biological properties and modulate therapeutic susceptibilities. As G12D-specific inhibitors are expected to enter the clinic, we sought to investigate the characteristics and outcomes of patients with KRAS G12D-m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cooper, Alissa J., Muzikansky, Alona, Lennerz, Jochen, Narinesingh, Farhaana, Mino-Kenudson, Mari, Hung, Yin P., Piotrowska, Zofia, Dagogo-Jack, Ibiayi, Sequist, Lecia V., Gainor, Justin F., Lin, Jessica J., Heist, Rebecca S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471201/ https://www.ncbi.nlm.nih.gov/pubmed/36118132 http://dx.doi.org/10.1016/j.jtocrr.2022.100390

Ejemplares similares

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2023)

Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2018)

Extrathoracic Metastases in Pleural Mesothelioma
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2023)

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience
por: Piper-Vallillo, A.J., et al.
Publicado: (2022)

Phase II Study of Cabozantinib in Patients With Bone Metastasis
por: Choy, Edwin, et al.
Publicado: (2022)

A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib
por: Schneider, Jaime L., et al.
Publicado: (2022)

Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution
por: Schneider, Jaime L., et al.
Publicado: (2023)

B-Cell Infiltrate in the Tumor Microenvironment Is Associated With Improved Survival in Resected Lung Adenocarcinoma
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2023)

ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients
por: Uruga, Hironori, et al.
Publicado: (2018)

Clinical and Imaging Features of Non-Small Cell Lung Cancer with G12C KRAS Mutation
por: Wu, Markus Y., et al.
Publicado: (2021)

Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2020)

Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition
por: Lin, Jessica J., et al.
Publicado: (2020)

Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer
por: Digumarthy, Subba R., et al.
Publicado: (2019)

Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
por: Digumarthy, Subba R., et al.
Publicado: (2019)

Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status?
por: Digumarthy, Subba R., et al.
Publicado: (2019)

Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics?
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2016)

Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study
por: Lin, J.J., et al.
Publicado: (2021)

Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2019)

Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
por: Mino-Kenudson, Mari
Publicado: (2016)

Significance of tumor spread through air spaces (STAS) in lung cancer from the pathologist perspective
por: Mino-Kenudson, Mari
Publicado: (2020)

COVID-19: a closer look at the pathology in two autopsied cases. Is the pericyte at the center of the pathological process in COVID-19?
por: Daisley, Hubert, et al.
Publicado: (2021)

The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2020)

Germline mutations and developmental mosaicism underlying EGFR-mutant lung cancer
por: Burr, Risa, et al.
Publicado: (2023)

Treating KRAS-mutant NSCLC: latest evidence and clinical consequences
por: Garrido, Pilar, et al.
Publicado: (2017)

The vasa vasorum of the large pulmonary vessels are involved in COVID-19
por: Daisley, Hubert, et al.
Publicado: (2021)

Role of imaging biomarkers in mutation-driven non-small cell lung cancer
por: Mendoza, Dexter P, et al.
Publicado: (2020)

Biology and impact of lineage plasticity in ALK-positive NSCLC: a narrative review
por: Meador, Catherine B., et al.
Publicado: (2023)

Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program
por: Santos, Edgardo S., et al.
Publicado: (2018)

Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC
por: Liu, Weiran, et al.
Publicado: (2016)

KRAS in NSCLC: State of the Art and Future Perspectives
por: Cascetta, Priscilla, et al.
Publicado: (2022)

Animal Models of Colitis-Associated Carcinogenesis
por: Kanneganti, Manasa, et al.
Publicado: (2011)

Implications of KRAS mutations in acquired resistance to treatment in NSCLC
por: Del Re, Marzia, et al.
Publicado: (2017)

Altered Transcriptional Control Networks with Trans-Differentiation of Isogenic Mutant-KRas NSCLC Models
por: Haley, John A., et al.
Publicado: (2014)

Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC
por: Xia, Meng, et al.
Publicado: (2020)

Infections of the Gastrointestinal Tract
por: Lauwers, Gregory, et al.
Publicado: (2010)

A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC
por: Moreno, Silvia, et al.
Publicado: (2021)

The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC
por: Weidhaas, Joanne B., et al.
Publicado: (2023)

Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations
por: Chatziandreou, Ilenia, et al.
Publicado: (2015)

Clinicopathological and prognostic significance of Twist overexpression in NSCLC
por: Li, Meng, et al.
Publicado: (2018)

Infections of the Gastrointestinal Tract
por: Lauwers, Gregory Y., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kp57kqk5eodn8t0g2bmd2hskc9